Levetiracetam Aurovitas (Levetiracetam)

Levetiracetam is an antiepileptic drug that reduces seizure activity by targeting neuronal excitability.

• Partial seizures: provides control of focal onset seizures, lowering both the number of episodes and their intensity, thereby improving daily functioning.
• Generalized tonic‑clonic seizures: decreases the frequency of bilateral convulsive seizures, helping to prevent loss of consciousness and injury.
• Myoclonic seizures: mitigates sudden, brief muscle jerks characteristic of myoclonic epilepsy, reducing disruption of activities.

• Levetiracetam binds to the synaptic vesicle protein SV2A, a key regulator of neurotransmitter release. This interaction modulates calcium‑dependent exocytosis, stabilizing neuronal membranes and decreasing hyper‑synchronised firing. By reducing the release of excitatory neurotransmitters, the drug lowers neuronal excitability and suppresses the propagation of seizure activity throughout the central nervous system. The precise mechanism remains partially understood, but the SV2A binding is considered central to its anticonvulsant effect.

Levetiracetam may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Dizziness: sensation of light‑headedness or imbalance.
• Fatigue: feeling unusually tired or weak.
• Headache: mild to moderate cranial pain.
• Nausea: upset stomach or urge to vomit.
• Irritability: mood changes or increased agitation.
• Somnolence: excessive sleepiness during the day.
• Blurred vision: temporary visual disturbances.

Serious or Rare Side Effects

• Severe allergic reaction: rash, swelling, or difficulty breathing.
• Mood disorders: depression, anxiety, or suicidal thoughts.
• Hematologic abnormalities: low blood cell counts.
• Hepatic dysfunction: elevated liver enzymes.
• Stevens‑Johnson syndrome: severe skin blistering.
• Multi‑organ failure: rare but life‑threatening systemic reaction.

When prescribing Levetiracetam, clinicians should consider several precautionary measures to ensure safe use.

• Renal impairment: adjust dose or monitor renal function in patients with reduced kidney clearance.
• Hepatic dysfunction: evaluate liver status before initiating therapy and observe for hepatic adverse events.
• Psychiatric history: monitor for mood changes, depression, or suicidal ideation, especially in patients with prior psychiatric disorders.
• Concomitant CNS depressants: use caution as combined effects may increase sedation or dizziness.
• Pregnancy and lactation: assess risk‑benefit ratio; limited data are available, so use only if clearly needed.
• Store at ambient temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Levetiracetam can interact with other medicines, affecting its efficacy or safety profile.

Major Interactions (Avoid)

• Carbamazepine: may reduce levetiracetam plasma levels, decreasing seizure control.
• Phenobarbital: can lower levetiracetam concentrations, potentially compromising effectiveness.
• Phenytoin: may increase clearance of levetiracetam, leading to subtherapeutic exposure.
• Topiramate: may increase risk of cognitive side effects when used together.

Moderate Interactions (Monitor Closely)

• Alcohol: combined use may enhance central nervous system depression and dizziness.
• Opioids: concurrent administration can increase sedation and respiratory depression risk.
• Other antiepileptics (e.g., valproate, lamotrigine): may require dose adjustments based on clinical response.
• Antidepressants (e.g., SSRIs): monitor for increased irritability or mood changes.